N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nykode Therapeutics ASA
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Total Equity
$152.1m
CAGR 3-Years
-3%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Total Equity
kr103.8m
CAGR 3-Years
-16%
CAGR 5-Years
-6%
CAGR 10-Years
0%
B
Bergenbio ASA
OSE:BGBIO
Total Equity
kr153.4m
CAGR 3-Years
-30%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Total Equity
kr51.3m
CAGR 3-Years
37%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Total Equity
kr318.8m
CAGR 3-Years
12%
CAGR 5-Years
47%
CAGR 10-Years
12%
T
Thor Medical ASA
OSE:TRMED
Total Equity
kr260m
CAGR 3-Years
-11%
CAGR 5-Years
-8%
CAGR 10-Years
17%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Total Equity?
Total Equity
152.1m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Total Equity amounts to 152.1m USD.

What is Nykode Therapeutics ASA's Total Equity growth rate?
Total Equity CAGR 5Y
32%

Over the last year, the Total Equity growth was 9%. The average annual Total Equity growth rates for Nykode Therapeutics ASA have been -3% over the past three years , 32% over the past five years .

Back to Top